Investing.com - DBV Technologies (NASDAQ: DBVT) reported third quarter EPS of $-0.170, $0.07 better than the analyst estimate of $-0.237. Revenue for the quarter came in at $2.4M...
Investing.com - DBV Technologies (NASDAQ: DBVT) reported second quarter EPS of $-0.260, $0.05 worse than the analyst estimate of $-0.210. Revenue for the quarter came in at $2.3M...
It is all about coronavirus treatments and vaccines for the biotech sector at the moment. A slew of biotechs is evaluating their pipeline drugs and vaccines for the treatment of...
DBV Technologies S.A. (NASDAQ:DBVT) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because DBVT is now in overbought...
As of late, it has definitely been a great time to be an investor in DBV Technologies S.A. (NASDAQ:DBVT) . The stock has moved higher by 5.3% in the past month, while it is also...
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow\u2019s milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn\u2019s disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00e9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Name | Last | Chg. % | Vol. |
|---|---|---|---|
TSLA | 203.44 | +1.86% | 39.49M |
NVDA | 774.70 | -1.56% | 14.88M |
AAPL | 181.12 | -0.83% | 14.14M |
AMD | 175.02 | -1.67% | 13.58M |
META | 484.63 | -0.50% | 4.77M |
SMCI | 826.35 | -2.91% | 2.54M |
BRKa | 623,775 | +1.05% | 11.07K |
| Name | Last | Chg. % | Vol. |
|---|---|---|---|
EBAY | 47.77 | +7.61% | 10.61M |
AXON | 292.40 | +7.57% | 580.17K |
A | 138.44 | +4.44% | 714.67K |
ALB | 133.31 | +3.67% | 1.02M |
UHS | 169.80 | +2.42% | 591.25K |
WY | 33.84 | +2.86% | 582.78K |
DLR | 141.64 | +2.47% | 362.69K |
| Name | Last | Chg. % | Vol. |
|---|---|---|---|
UNH | 487.18 | -5.11% | 3.61M |
HSIC | 75.18 | -3.43% | 376.86K |
AMAT | 196.79 | -2.99% | 2.21M |
RMD | 176.13 | -2.68% | 241.76K |
ALGN | 304.38 | -2.77% | 138.05K |
VTRS | 12.81 | -3.18% | 6.66M |
PDD | 125.18 | -2.45% | 1.66M |
| Name | Last | Chg. % | Vol. |
|---|---|---|---|
NVDA | 774.70 | -1.56% | |
TSLA | 203.63 | +1.95% | |
PANW | 309.91 | -1.54% | |
AAPL | 181.21 | -0.78% | |
MARA | 31.79 | +4.87% |
| \n | \n Dow | \n\n | \n \n | \n \n | \n \n | \n
| \n | \n S&P 500 | \n\n | \n \n | \n \n | \n \n | \n
| \n | \n Nasdaq | \n\n | \n \n | \n \n | \n \n | \n
| \n | \n VIX | \n\n | \n \n | \n \n | \n \n | \n
| \n | \n Gold | \n\n | \n \n | \n \n | \n \n | \n
| \n | \n Oil | \n\n | \n \n | \n \n | \n \n | \n
| Previous Close | \r\n
|---|
| $0.8270 | \r\n
| \r\n | \r\n Symbol \r\n Company\r\n | \r\n \r\n Price \r\n Chg/Chg %\r\n | \r\n
|---|
| \r\n \r\n | \r\n\r\n \r\n \r\n \r\n \r\n \r\n \r\n | \r\n \r\n \r\n \r\n \r\n \r\n | \r\n
| 5 Day | \r\n\r\n
| \r\n
| 1 Month | \r\n\r\n
| \r\n
| 3 Month | \r\n\r\n
| \r\n
| YTD | \r\n\r\n
| \r\n
| 1 Year | \r\n\r\n
| \r\n
Shares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for its experimental peanut allerg...
\n\n \n\nDbv Technologies SA to Discuss the EPOPEX Data Call Transcript
\n\n \n\nQ3 2023 Dbv Technologies SA Earnings Call Transcript
\n\n \n\nHalf Year 2023 Dbv Technologies SA Earnings Call Transcript
\n\n \n\nDbv Technologies SA at Goldman Sachs Healthcare Conference Transcript
\n\n \n\nDbv Technologies SA at JMP Securities Life Sciences Conference Transcript
\n\n \n\nDbv Technologies SA FDA Regulatory Call Transcript
\n\n \n\nFull Year 2022 Dbv Technologies SA Earnings Call Transcript
\n\n \n\nQ3 2022 Dbv Technologies SA Earnings Call Transcript
\n\n \n\nDbv Technologies SA to Discuss the VITESSE Study Call Transcript
\n\n \n\nDbv Technologies SA to Discuss Positive Topline Results from Phase 3 EPITOPE Trial Call Transcript
\n\n \n\nQ1 2022 DBV Technologies SA Earnings Call Transcript
\n\n \n\nFull Year 2021 DBV Technologies SA Earnings Call Transcript
\n\n \n\nQ3 2021 DBV Technologies SA Earnings Call Transcript
\n\n \n\nHalf Year 2021 DBV Technologies SA Earnings Call Transcript
\n\n \n\nDBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
\n| Name | \nChg % | \nMarket Cap | \n
|---|---|---|
| Ionis Pharmaceuticals Inc. | \n$6.72B | \n|
| Alnylam Pharmaceuticals Inc. | \n$19.98B | \n
| Label | \nValue | \n
|---|---|
| \n | \n |
\n The\u202fbid\u202f&\u202fask\u202frefers to the price that an investor is willing to buy or sell a stock. The\u202fbid\u202fis the highest amount that a buyer is currently willing to pay, whereas the ask\u202fis the lowest\n \n amount that a seller is currently willing to sell. The numbers next to the bid/ask are the \u201csize\u201d. The bid size displays the total amount of desired shares to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time.
\r\n\r\nThe\u202fbid-ask spread\u202fcan indicate a stock\u2019s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a\u202f market order\u202for\u202flimit order\u202fwhen trading, helping you to optimize your price and have a successful order execution.
\r\n\r\nReal-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit\u202fNasdaq Data Link's products page.\n \n
| Label | \nValue | \n
|---|---|
| \n | \n |
![](\"/themes/nsdq/src/assets/images/NasdaqLink.svg\")
Powered by Nasdaq Data Link ![](\"/themes/nsdq/src/assets/images/Subtract.svg\")
\n Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.
\n| \n | |
|---|---|
| \n | \n |
| \n |
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
\n**Green highlights the top performing ETF by % change in the past 100 days.
\n| Name | \nTitle | \n
|---|
\u00a0
\n\nData provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at\u00a0data.nasdaq.com.
\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tMorningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tnot under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tcompanies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
| \n\t\tMetric\n\t | \n\t\tDBVT\n\t | \n\t\tKDNY\n\t | \n\t\tVKTX\n\t |
|---|---|---|---|
Price/Earnings (Normalized) | \u2014 | \u2014 | \u2014 |
Price/Book Value | 1.10 | 7.59 | 24.44 |
Price/Sales | \u2014 | 482.40 | \u2014 |
Price/Cash Flow | \u2014 | \u2014 | \u2014 |
| \n\t\tMetric\n\t | \n\t\tDBVT\n\t | \n\t\tKDNY\n\t | \n\t\tVKTX\n\t |
|---|---|---|---|
Quick Ratio | 5.28 | 5.72 | 18.92 |
Current Ratio | 5.38 | 5.82 | 19.19 |
Interest Coverage | \u2014 | \u2014 | \u2014 |
| \n\t\tMetric\n\t | \n\t\tDBVT\n\t | \n\t\tKDNY\n\t | \n\t\tVKTX\n\t |
|---|---|---|---|
Return on Assets (Normalized) | \u221241.58% | \u221237.41% | \u221223.50% |
Return on Equity (Normalized) | \u221252.79% | \u221247.73% | \u221225.01% |
Return on Invested Capital (Normalized) | \u221252.52% | \u221243.85% | \u221230.29% |
| \n\t\t\t\t\tTicker\n\t\t\t\t | \n\t\t\t\t\tName\n\t\t\t\t | \n\t\t\t\t\tMorningstar Rating for Stocks\n\t\t\t\t | \n\t\t\t\t\tEconomic Moat\n\t\t\t\t | \n\t\t\t\t\tMarket Cap\n\t\t\t\t |
|---|---|---|---|---|
\n\t\tNVO\n\t | Novo Nordisk A/S ADR | Dvmh | $541.7 Bil | |
\n\t\tVRTX\n\t | Vertex Pharmaceuticals Inc | Fpysq | $111.3 Bil | |
\n\t\tREGN\n\t | Regeneron Pharmaceuticals Inc | Fkrdfz | $109.0 Bil | |
\n\t\tMRNA\n\t | Moderna Inc | Nrbq | $36.8 Bil | |
\n\t\tARGX\n\t | argenx SE ADR | Zyfny | $24.3 Bil | |
\n\t\tBNTX\n\t | BioNTech SE ADR | Pypp | $22.1 Bil | |
\n\t\tALNY\n\t | Alnylam Pharmaceuticals Inc | Zgtzyr | $20.0 Bil | |
\n\t\tBMRN\n\t | Biomarin Pharmaceutical Inc | Fmxqb | $17.1 Bil | |
\n\t\tRPRX\n\t | Royalty Pharma PLC Class A | Qpghnqx | $14.0 Bil | |
\n\t\tINCY\n\t | Incyte Corp | Mjrjhg | $13.7 Bil |
| Label | \nValue | \n
|---|---|
| \n | \n |
\n The\u202fbid\u202f&\u202fask\u202frefers to the price that an investor is willing to buy or sell a stock. The\u202fbid\u202fis the highest amount that a buyer is currently willing to pay, whereas the ask\u202fis the lowest\n \n amount that a seller is currently willing to sell. The numbers next to the bid/ask are the \u201csize\u201d. The bid size displays the total amount of desired shares to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time.
\r\n\r\nThe\u202fbid-ask spread\u202fcan indicate a stock\u2019s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a\u202f market order\u202for\u202flimit order\u202fwhen trading, helping you to optimize your price and have a successful order execution.
\r\n\r\nReal-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit\u202fNasdaq Data Link's products page.\n \n
| Label | \nValue | \n
|---|---|
| \n | \n |
Powered by Nasdaq Data Link \n Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.
\n| \n | |
|---|---|
| \n | \n |
| \n |
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
\n**Green highlights the top performing ETF by % change in the past 100 days.
\n| Name | \nTitle | \n
|---|
\u00a0
\n\nData provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at\u00a0data.nasdaq.com.
\n\n![\"Read](\"https://ei.marketwatch.com/Multimedia/2018/11/18/Photos/ZH/MW-GY737_peanut_20181118222841_ZH.jpg?size=1.777777777777778&width=220)
\n \n \n ![\"Read](\"https://s.wsj.net/public/resources/images/ON-CH700_Peanut_B1280_20171017190233.jpg?size=1.777777777777778&width=220)
\n \n \n ![\"Morningstar\"](\"/assets/img/morningstar-50px.d304f16.svg\")